Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
03 March 2022 | Story Dr Nitha Ramnath | Photo istock
Online news

The University of the Free State (UFS) has joined The Conversation Africa (TCA) as a funding partner.  TCA, a not-for-profit media initiative, is part of a global platform that publishes articles written by academics and researchers.  The platform’s objective is to make the knowledge produced in the academy accessible, easy to understand, and freely available to the general public. Articles are published daily on the TC-Africa website - https://theconversation.com/africa. 

The platform uses a Creative Commons republishing model. This means articles can be republished by other media on the continent and internationally, ensuring even greater reach to audiences including academics, policy makers, funders, and the general public. 

To date, more than 55 UFS researchers and academics have published with TCA, and their articles have garnered more than 1,3 million readers globally. UFS researchers and academics are encouraged to publish with The Conversation. 

As part of the partnership, TCA will run writing workshops for UFS academics and researchers who want to enhance their writing and science communication skills. Dates for these will be announced soon.

How you can publish with The Conversation Africa

• Engage with The Conversation Africa editors when they contact you directly to write about your research area and expertise. The articles are short, ± 800 to 1 000 words.

• Pitch your idea for an article directly to The Conversation Africa here   

• Register as an author, and set up a profile

• Engage with the Communication and Research offices. Every week, The Conversation Africa sends an expert request for expert authors on topical issues to the Communication and Research offices, which can identify researchers. 
- Interested researchers are put into contact with the relevant editor at The Conversation to discuss the potential article

Why should you get published on The Conversation Africa?

Benefits for researchers and academics:

• Articles on the platform help to raise the profile of academics, often leading to policy engagement with governments, businesses, industry or professional bodies, conference invitations, academic collaborations, and further media exposure. 
• In the course of writing, academics get bespoke editorial assistance from the team working in consultation with them. 
• The opportunity to take part in a hands-on science communication writing workshop.
• Readership and republication metrics for each published article.
• A global readership with up to 1,2 million readers monthly.

Benefits for Communication and Marketing and the Research office:

• Provides well-curated, ready-to-use communication material for websites and social media. 
• Helps to profile the work of the university for marketing, communication, and awareness.
• Provides media exposure to the talent pool of UFS academics and researchers. 

Benefits for and across the university:

• Shines a spotlight on the excellent research and innovation at the UFS.
• Demonstrates the UFS’ commitment to facilitating greater engagement with society and promoting interdisciplinary communications.
• Visibility for the institution and researchers nationally and globally.
• Access to institutional analytics, including detailed data on the content published by UFS researchers.

Contact The Conversation Africa:

To arrange departmental meetings and introductory sessions to The Conversation Africa team, contact: Pfungwa Nyamukachi, Strategic Partnerships and Stakeholder Relations Manager: pfungwa.nyamukachi@theconversation.com 

News Archive

HIV Cure – Just another fantasy?
2016-07-27

Description: HIV Cure – Just another fantasy? Tags: HIV Cure – Just another fantasy?

Dr Dominique Goedhals, Prof John Frater,
Dr Thabiso Mofokeng and Dr Jacob Jansen van Vuuren,
attended the lecture. Prof Frater has been working in
collaboration with the UFS Department of Internal
Medicine on HIV resistance and HIV immunology
since 2007.

Photo: Nonsindiso Qwabe

Twenty-years ago, after a person had been diagnosed with HIV, their lifespan did not exceed three years, but thanks to the success of antiretroviral therapy programmes, life expectancy has risen by an average of ten years. However, is antiretroviral therapy always going to be for life? This is the societal issue that Professor John Frater, addressed in his talk at the University of the Free State. He is an MRC Senior Clinical Fellow, Associate Professor and Honorary Consultant Physician in Infectious Diseases at  Oxford University.

Antiretroviral medicine therapeutic

The discovery of antiretroviral therapy - the use of HIV medicines to treat the virus - has had a positive effect on the health and well-being of people living with it, improving their quality of life. Unfortunately, if treatment is stopped, HIV rebounds to the detriment of the patient. Now, research has shown that some patients, who are treated soon after being infected by HIV, may go off treatment for prolonged periods. Work is being done to predict who will be able to stop treatment.

“The difference made by starting treatment earlier is enormous. Delaying treatment is denying yourself the right to health,” Professor Frater says. However, this does not mean that the virus is cured. “A person can live for ten years without being on HIV treatment, but is that enough?” he went on to ask.

Healthy lifestyles encouraged

The National Department of Health will adopt a test and treat immediately strategy later this year to improve patient health and curb the spread of HIV. ,This is another reason why everybody should know their status and start treatment as soon as possible.

Search for a cure continues

More research is being conducted to establish whether HIV can be eradicated. Remission gives hope that a permanent cure may be found eventually. “Will a cure for HIV ever be found? Time will tell,” he concluded.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept